NASDAQ:ORPNBioblast Pharma Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bioblast Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.50 +6.21 (+117.39 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range$11.50Now: $11.50▼$11.5050-Day Range$11.50MA: $19.65▼$28.4952-Week Range$6.16Now: $11.50▼$30.00VolumeN/AAverage VolumeN/AMarket Capitalization$4.83 millionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bioblast Pharma. Previous Next 3.2 Community Rank Outperform VotesBioblast Pharma has received 212 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioblast Pharma has received 119 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioblast Pharma has received 64.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bioblast Pharma and other stocks. Vote “Outperform” if you believe ORPN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORPN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioblast Pharma does not currently pay a dividend.Dividend GrowthBioblast Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioblast Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 4.47% of the stock of Bioblast Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioBioblast Pharma has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORPN Previous Symbol CUSIPN/A CIK1596812 Webbioblastpharma.com Phone972-3573-6632Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book1.52Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares420,000Market Cap$4.83 million Next Earnings DateN/A OptionableNot Optionable Receive ORPN News and Ratings via Email Sign-up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Bioblast Pharma (NASDAQ:ORPN) Frequently Asked Questions When did Bioblast Pharma's stock split? How did Bioblast Pharma's stock split work? Bioblast Pharma shares reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Bioblast Pharma stock prior to the reverse split would have 13 shares after the split. Has Bioblast Pharma been receiving favorable news coverage? News headlines about ORPN stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bioblast Pharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Bioblast Pharma. Who are some of Bioblast Pharma's key competitors? Some companies that are related to Bioblast Pharma include Uluru (ULUR), KemPharm (KMPH), MYOS (MYOS), Bio-Path (BPTH), Adial Pharmaceuticals (ADIL), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Pharmaxis (PXSLY), Provectus Biopharmaceuticals (PVCT), Tetraphase Pharmaceuticals (TTPH), Mateon Therapeutics (MATN), ProPhase Labs (PRPH), China SXT Pharmaceuticals (SXTC), Regulus Therapeutics (RGLS), VIVUS (VVUS) and Teligent (TLGT). View all competitors. What other stocks do shareholders of Bioblast Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), SLS International (SLS), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO). Who are Bioblast Pharma's key executives? Bioblast Pharma's management team includes the following people: Dr. Dalia Megiddo M.B.A., Ph.D., M.D., MBA, Co-Founder, MD, CEO & Director (Age 67)Dr. Warren W. Wasiewski, VP of R&D (Age 67)Prof. Avizohar Argov M.D., Special Medical Advisor to the Chief Exec. Officer and Member of Scientific Advisory Board (Age 72) What is Bioblast Pharma's stock symbol? Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN." What is Bioblast Pharma's stock price today? One share of ORPN stock can currently be purchased for approximately $11.50. How big of a company is Bioblast Pharma? Bioblast Pharma has a market capitalization of $4.83 million. What is Bioblast Pharma's official website? The official website for Bioblast Pharma is bioblastpharma.com. How can I contact Bioblast Pharma? Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The biopharmaceutical company can be reached via phone at 972-3573-6632 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
